S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
China Has Stunning Lithium Chokehold On U.S. (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
China Has Stunning Lithium Chokehold On U.S. (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
China Has Stunning Lithium Chokehold On U.S. (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
China Has Stunning Lithium Chokehold On U.S. (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
China Has Stunning Lithium Chokehold On U.S. (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
China Has Stunning Lithium Chokehold On U.S. (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
China Has Stunning Lithium Chokehold On U.S. (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
China Has Stunning Lithium Chokehold On U.S. (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
China Has Stunning Lithium Chokehold On U.S. (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
China Has Stunning Lithium Chokehold On U.S. (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
China Has Stunning Lithium Chokehold On U.S. (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
China Has Stunning Lithium Chokehold On U.S. (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
NASDAQ:TNDM

Tandem Diabetes Care - TNDM Stock Forecast, Price & News

$42.29
+1.27 (+3.10%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$40.54
$42.47
50-Day Range
$35.72
$56.15
52-Week Range
$33.51
$155.86
Volume
555,164 shs
Average Volume
968,588 shs
Market Capitalization
$2.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$76.93

Tandem Diabetes Care MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
81.9% Upside
$76.93 Price Target
Short Interest
Healthy
8.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.64
Upright™ Environmental Score
News Sentiment
1.03mentions of Tandem Diabetes Care in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.76) to ($0.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Medical Sector

69th out of 1,027 stocks

Surgical & Medical Instruments Industry

5th out of 101 stocks

TNDM stock logo

About Tandem Diabetes Care (NASDAQ:TNDM) Stock

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Stock News Headlines

Tandem Diabetes Care: Undervalued Technology Leader
Tandem Diabetes (TNDM) Q3 Earnings Miss, Sales View Cut
Barclays Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
Tandem Diabetes Shares Slump After Dismal Annual Outlook
5 Analysts Have This to Say About Tandem Diabetes Care
Tandem Diabetes Care, Inc. (TNDM)
Tandem Diabetes (TNDM) Faces Expense Woes, Macro Issues
See More Headlines
Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Company Calendar

Last Earnings
11/03/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/28/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNDM
Fax
N/A
Employees
2,000
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$76.93
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$43.00
Forecasted Upside/Downside
+81.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$15.57 million
Pretax Margin
-8.30%

Debt

Sales & Book Value

Annual Sales
$702.80 million
Cash Flow
$0.53 per share
Book Value
$6.82 per share

Miscellaneous

Free Float
62,884,000
Market Cap
$2.72 billion
Optionable
Optionable
Beta
0.89

Social Links


Key Executives

  • Mr. John F. SheridanMr. John F. Sheridan (Age 67)
    Pres, CEO & Director
    Comp: $1.6M
  • Ms. Leigh A. VossellerMs. Leigh A. Vosseller (Age 49)
    Exec. VP, CFO & Treasurer
    Comp: $764.64k
  • Mr. David B. Berger Esq. (Age 52)
    Exec. VP & COO
    Comp: $765.11k
  • Ms. Susan M. MorrisonMs. Susan M. Morrison (Age 43)
    Exec. VP & Chief Admin. Officer
    Comp: $764.35k
  • Mr. Brian B. HansenMr. Brian B. Hansen (Age 54)
    Exec. VP & Chief Commercial Officer
    Comp: $781.22k
  • Ms. Elizabeth Anne GasserMs. Elizabeth Anne Gasser (Age 46)
    Exec. VP & Chief Strategy Officer
    Comp: $764.64k
  • Mr. Rick A. Carpenter (Age 59)
    Chief Technical Officer
  • Ms. Shannon M. Hansen (Age 56)
    Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Mr. Ross Sylvia
    VP of Marketing
  • Mr. Tom Fox
    Sr. VP of HR & Organizational Devel.













TNDM Stock - Frequently Asked Questions

Should I buy or sell Tandem Diabetes Care stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNDM shares.
View TNDM analyst ratings
or view top-rated stocks.

What is Tandem Diabetes Care's stock price forecast for 2023?

8 analysts have issued 12-month price objectives for Tandem Diabetes Care's shares. Their TNDM share price forecasts range from $43.00 to $130.00. On average, they expect the company's stock price to reach $76.93 in the next year. This suggests a possible upside of 81.9% from the stock's current price.
View analysts price targets for TNDM
or view top-rated stocks among Wall Street analysts.

How have TNDM shares performed in 2022?

Tandem Diabetes Care's stock was trading at $150.52 at the start of the year. Since then, TNDM shares have decreased by 71.9% and is now trading at $42.29.
View the best growth stocks for 2022 here
.

When is Tandem Diabetes Care's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our TNDM earnings forecast
.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) released its quarterly earnings results on Wednesday, November, 3rd. The medical device company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.08 by $0.01. The medical device company had revenue of $179.63 million for the quarter, compared to the consensus estimate of $172.80 million. Tandem Diabetes Care had a negative trailing twelve-month return on equity of 8.34% and a negative net margin of 8.59%. During the same quarter last year, the company earned ($0.09) earnings per share.

When did Tandem Diabetes Care's stock split?

Tandem Diabetes Care's stock reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $800.00 million-$805.00 million, compared to the consensus revenue estimate of $836.40 million.

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.63%), BlackRock Inc. (9.48%), State Street Corp (2.77%), Eminence Capital LP (2.47%), Bellevue Group AG (2.44%) and Stephens Investment Management Group LLC (1.52%). Insiders that own company stock include Brian B Hansen, Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends
.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $42.29.

How much money does Tandem Diabetes Care make?

Tandem Diabetes Care (NASDAQ:TNDM) has a market capitalization of $2.72 billion and generates $702.80 million in revenue each year. The medical device company earns $15.57 million in net income (profit) each year or ($1.07) on an earnings per share basis.

How many employees does Tandem Diabetes Care have?

The company employs 2,000 workers across the globe.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The official website for the company is www.tandemdiabetes.com. The medical device company can be reached via phone at (858) 366-6900 or via email at smorrison@tandemdiabetes.com.

This page (NASDAQ:TNDM) was last updated on 12/8/2022 by MarketBeat.com Staff